{
  "name" : "zero.sci-hub.se_5580_fde25e56768e3da6c2ae57e8ea377727_balzano2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis",
    "authors" : [ "G. Balzano", "P. Maffi", "R. Nano", "A. Mercalli", "R. Melzi", "F. Aleotti", "A. Zerbi", "F. De Cobelli", "F. Gavazzi", "P. Magistretti", "M. Scavini", "J. Peccatori", "A. Secchi", "F. Ciceri", "A. Del Maschio", "M. Falconi" ],
    "emails" : [ "piemonti.lorenzo@hsr.it" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Autologous Islet Transplantation in Patients"
    }, {
      "heading" : "Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis",
      "text" : ""
    }, {
      "heading" : "G. Balzano1, P. Maffi2, R. Nano2, A. Mercalli2,",
      "text" : ""
    }, {
      "heading" : "R. Melzi2, F. Aleotti1, A. Zerbi3, F. De Cobelli4,",
      "text" : ""
    }, {
      "heading" : "F. Gavazzi3, P. Magistretti2, M. Scavini2,",
      "text" : ""
    }, {
      "heading" : "J. Peccatori5, A. Secchi6,7, F. Ciceri5,",
      "text" : ""
    }, {
      "heading" : "A. Del Maschio4,7, M. Falconi1,7 and",
      "text" : ""
    }, {
      "heading" : "L. Piemonti2,*",
      "text" : "1Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy 2Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy 3Pancreatic Surgery Section, Department of General Surgery, IRCCS Istituto Clinico Humanitas, Milano, Italy 4Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy 5Units of Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy 6Clinical Transplant Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy 7Vita-Salute San Raffaele University, Milan, Italy *Corresponding author: Lorenzo Piemonti, piemonti.lorenzo@hsr.it\nIslet autotransplantation (IAT) is usually performed in patients undergoing pancreatic surgery for chronic pancreatitis. In the present series, IAT was offered also to patients undergoing pancreatic surgery for both nonmalignant and malignant diseases, having either completion pancreatectomy as treatment for severe pancreatic fistulas (n = 21) or extensive distal pancreatectomy for neoplasms of the pancreatic neck (n = 19) or pancreatoduodenectomy because of the high risk of pancreatic fistula (n = 32). Fifty-eight of 72 patients who were eligible to this broader spectrum of indication actually received IAT. There was no evidence of a higher-than-expected rate of major complications for pancreatectomy. Forty-five patients receiving IAT were still alive at the time of the last scheduled follow-up (1375 365 days). Eighteen (95%) of 19 and 11 (28%) of 39 patients reached insulin independence after partial or total pancreatectomy, respectively. The metabolic results were dependent on the transplanted islet mass. Thirty-one of 58 patients had malignant diseases of the pancreas or periampullary region, and only three patients developed ex novo liver metastases after IAT (median follow-up 914 382 days). Our data\ndemonstrate the feasibility, efficacy, and safety of IAT for a broader spectrum of clinical indications beyond chronic pancreatitis.\nAbbreviations: HbA1c, glycated hemoglobin; HR, hazard ratio; IAT, islet autotransplantation; IEQ, islet equivalent; TCAE, Terminology Criteria for Adverse Events\nReceived 01 July 2015, revised 24 November 2015 and accepted for publication 26 November 2015"
    }, {
      "heading" : "Introduction",
      "text" : "Pancreatic surgery is a technically demanding major procedure burdened by a significant rate of complications (1), including death (2,3). In the past decades, consolidation of surgical expertise, centralization of pancreatic surgery in high-volume centers, and overall improvement of medical support of surgical patients (4–6) have resulted in a steep decline of pancreatic surgery mortality from ~25% during the 1960s to the current rate of <5% (3,7–9). As the survival of patients after pancreatic surgery has increased (10), attention has broadened to include patients’ quality of life (11–13). Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19). Islet autotransplantation (IAT) is a valuable option to avoid or minimize postsurgery pancreatogenic diabetes (20). In the past, IAT has been performed almost exclusively in patients undergoing pancreatectomy because of chronic pancreatitis, successfully preserving b-cell mass and preventing diabetes after major pancreatic resections (21–24). Additional indications for IAT other than chronic pancreatitis are still controversial (25–27). Recently, our group has set forth broader indications for IAT (27,28) and published a small series of patients to explore the possibility of extending IAT to patients with known malignancy having either (i) completion pancreatectomy as treatment for severe pancreatic fistulas, (ii) extensive distal pancreatectomy for neoplasms of the pancreatic neck, or (iii) total pancreatectomy because of preoperative assessment of increased anastomotic risk. A preliminary short-term assessment\n1812\n© Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons\ndoi: 10.1111/ajt.13656"
    }, {
      "heading" : "American Journal of Transplantation 2016; 16: 1812–1826",
      "text" : "Wiley Periodicals Inc.\ndocumented feasibility of “extended” IAT indications for the prevention of postsurgery pancreatogenic diabetes (27,28). In this study, we report the long-term assessment in a larger cohort of 72 patients who were eligible for IAT according to our IAT extended indications."
    }, {
      "heading" : "Methods",
      "text" : ""
    }, {
      "heading" : "Patients",
      "text" : "From November 2008 to October 2015, all patients scheduled for pancreatic surgery at the Pancreatic Disease Unit of the Department of Surgery of the San Raffaele Scientific Institute (Milan, Italy) were screened to assess eligibility for IAT according to our extended indications (27,28). Moreover, since July 2013 the Islet Processing Facility of the San Raffaele Scientific Institute acted as remote islet isolation center for the IRCCS Istituto Clinico Humanitas (Rozzano, Italy), a second surgical site 15 miles away. Indications for IAT were as for the Milan Protocol (see Balzano and Piemonti (27) and Table 1]. Local ethic committee approval was obtained for the assessment of transplantation follow-up, and all patients signed an informed consent before enrollment in the study (ClinicalTrials.gov NCT01702051).\nIslet isolation, purification, and transplantation Islets were isolated and purified according to the automated method originally described by Ricordi (29), and their number was expressed as islet equivalent (IEQ). Evidence of no microbial contamination, as documented by a negative Gram stain immediately before transplant, was mandatory. The purified islets were transplanted back via infusion into the portal vein, either intraoperatively, when the clinical and logistic conditions allowed it, or, within 48 h, by percutaneous transhepatic cannulation of the portal vein under ultrasonographic or fluoroscopic guidance. In patients in whom infusion into the portal vein was contraindicated, islets were infused in the bone marrow at the level of the superoposterior iliac crest, as previously described (30)."
    }, {
      "heading" : "Perioperative monitoring and follow-up",
      "text" : "Assessment of portal vein patency was performed through Doppler ultrasound at days 1, 15, and 30. Beta-cell function was assessed, as previously described (31), by the measurement of fasting C-peptide (defined as positive for levels ≥0.09 ng/mL), glycated hemoglobin (HbA1c) levels, fasting glycemia, and average daily insulin requirement. In case of malignancy, adjuvant chemotherapy or radiotherapy was administered when indicated, and computed tomography scan and blood tumor markers were performed every 3 or 6 months, according to the risk of cancer recurrence. Adverse events related to the islet infusion procedure were recorded and classified according to the Terminology Criteria for Adverse Events (TCAE) in Trials of Adult Pancreatic Islet Transplantation Version 4.1 (16 July 2008) http:// www.isletstudy.org/CITDocs/CIT-TCAE%20V4.pdf. Complications of pancreatic surgery were recorded and classified according to the Dindo– Clavien classification (32)."
    }, {
      "heading" : "Study definitions",
      "text" : "Insulin independence: Insulin independence was defined as no need for exogenous insulin, with adequate glycemic control (i.e. HbA1c <7%, fasting glucose levels <140 mg/dL >3 times per week, and 2-h postprandial levels <180 mg/dL >4 times per week).\nPartial graft function: Partial graft function was defined as fasting C-peptide level ≥0.2 ng/mL, need for exogenous insulin, or inadequate\nglycemic control (i.e. HbA1c ≥7%, fasting glucose levels ≥140 mg/dL >3 times per week, and 2-h postprandial levels ≥180 mg/dL >4 times per week).\nAmerican Journal of Transplantation 2016; 16: 1812–1826 1813\nGraft loss: Graft loss includes “primary nonfunction” (i.e. fasting C-peptide level <0.2 ng/mL after islet infusion) and “complete graft loss” (an initial increase in fasting C-peptide levels followed by a decrease to <0.2 ng/mL)."
    }, {
      "heading" : "Statistical analysis",
      "text" : "All statistical analyses were performed using the SPSS 20.0 statistical software (SPSS Inc, Chicago, IL). Data are presented as mean standard error of the mean or median (interquartile range) as appropriate.\nRemoved pancreas\nweight (g)\n74 (67–87.5) 67 (54.2–81.7) 35 (30–45) 59.5 (48.5–80.5) 59 (40–75.7)\nIslet yield (IEQ)/g\npancreas\n1309 (654–1633) 2363 (1401–3520) 2190 (1700–4395) 2079 (1265–3536) 2175 (1325–3551)\nTransplanted 2 28 17 13 60 Inadequate for IAT due to:\nLow islet number (IEQ/kg <50) 1 (Patient 35) 1 (Patient 23) 1 (Patient 38) 2 (Patients 9, 57) 5 Bacterial\ncontamination\n0 2 (Patients 47, 60) 0 5 (Patients 31, 42,\n45, 52, 62)\n7\nCritically ill 0 1 (Patient 28) 0 1 (Patient 30) 2 Positive resection\nmargin\n0 0 1 (Patient 40) 0 1\nSite BM 0 5 (Patients 7, 14,\n17, 53, 64)\n0 2 (Patients 5, 22) 7\nIslet infused\n(IEQ/kg)\n2015 (1007–3023) 2129 (1564–2665) 1036 (594–1565) 1912 (1191–2476) 1697 (1069–2413)\nFresh/cultured islets 0/2 7/21 1/16 2/11 10/50 Culture time (h) 19.5 (16–23) 15 (0–18) 16 (14–16.5) 16 (11–19) 15 (13–18) Islet purification (%) 40 (20–60) 55 (30–80) 50 (20–70) 25 (15–45) 45 (20–70) Tissue volume (mL) 2.5 (1–4) 1.5 (1–1.62) 1.75 (1–4.5) 4 (2.25–5.75) 1.5 (1–4) D Portal vein pressure (cm\nH2O)\n2 (0–4) 1 (0–2) 1 (0–1.5) 1 (1–3.5) 1 (0–2)\nIAT, islet autotransplantation; BMI, body mass index; IEQ, islet equivalent; BM, bone marrow. 1Adenocarcinoma of the ampulla of Vater (n = 11), adenocarcinoma of the distal bile duct (n = 6), adenoma of the duodenum and papilla of Vater (n = 3), duodenal gagliocytic paraganglioma (n = 1). 2Serous cystadenoma (n = 5), mucinous cystadenoma (n = 3), intraductal papillary mucinous neoplasm (n = 5), solid-pseudopapillary neoplasm (n = 2). 3Gastrointestinal stromal tumor (patient 38), sequelae after iatrogenic duodenal perforation (patient 34), main bile duct inflammation (patient 55).\n1814 American Journal of Transplantation 2016; 16: 1812–1826\nContinuous variables were compared with use of the Student’s t-test (variables with a normal distribution) or Wilcoxon sign-rank test (variables with a nonnormal distribution) and categorical variables with the v2 test or Fisher’s exact test as appropriate. Survival was estimated according to Kaplan–Meier analysis. All tests were conducted using an a level of 0.05 to indicate statistical significance."
    }, {
      "heading" : "Results",
      "text" : ""
    }, {
      "heading" : "Patients and surgery",
      "text" : "A total of 75 patients met the criteria for IAT (including 11 followed at the remote surgical site). Specifically, three (4%) patients underwent subtotal pancreatectomy for chronic pancreatitis (criterion A); 32 (42.6%) patients were candidates for total pancreas resection and simultaneous IAT based on a preoperative assessment of increased anastomotic risk (criterion B); 19 (25.3%) patients were candidates to extended distal pancreatectomy and simultaneous IAT for lesions of the pancreatic body-neck region (criterion C); and 21 (28%) patients were candidates for salvage IAT after relaparotomy because of a grade C pancreatic fistula following pancreaticoduodenectomy (19 patients, completion pancreatectomy) or enucleation (two patients, distal pancreatectomy) (criterion D). Patient and transplant charac-\nteristics, stratified by eligibility criteria, are shown in Table 2. Due to the low number, the group meeting criterion A was not included in the analysis. A flow diagram of the analyzed groups including 72 patients is shown in Figure 1.\nSimultaneous IAT after total pancreatectomy (criterion B) Four (12.5%) of 32 patients who were candidates for IAT in this group were not transplanted (Figure 1, Table 2): three patients had islet preparations with an insufficient number of islets (patient 23; IEQ/kg <50) or that were inadequate because of bacterial contamination (patients 47 and 60), and one patient (patient 28) developed immediate postpancreatectomy complications contraindicating IAT (intraoperative malignant cardiac arrhythmia requiring cardiac resuscitation). The median number of infused islets was 2129 (1564–2665) IEQ/kg. The median postoperative hospital stay was 12 (10–15) days. Sixteen (57.1%) of 28 patients had postpancreatectomy complications (Table 3), but only five (17.8%) patients had major complications (grade >2). Complications related to IAT occurred in six (21.4%) of 28 patients, and in two (7.1%; patients 37 and 33), they were were potentially serious (TCAE score >3; Table 3). Five patients had\n32 21 19Candidates\n28 13 17\n22 -------------\n5 -------------\n1\n7 -----\n2 -----\n2\n2 -------------\n14 -------------\n1\n0 -----\n2 -----\n0\nTotal pancreatectomy\nN=39\nPar al pancreatectomy\nN=19\nTransplanted\nMalignant ------------- No/low malignant ------------- No neoplasia\nSimultaneous IAT a er total pancreatectomy\nSimultaneous IAT a er extended\ndistal pancreatectomy\nSalvage IAT a er relaparotomy\nN=31\nN=23\nFigure 1: Flow diagram of groups. IAT, islet autotransplantation.\nAmerican Journal of Transplantation 2016; 16: 1812–1826 1815\nbleeding related to the percutaneous portal vein access procedure: in three cases, the bleeding did not require intervention (patients 32, 43, and 44); one case required only a blood transfusion (patient 37), and one case required blood transfusion and surgery (patient 33). Left branch portal vein thrombosis occurred in one patient (patient 59) and resolved after anticoagulation therapy with low-molecular-weight heparin. On October 1, 2015, the median follow-up was 839 89 days, and 20 (71.4%) of 28 patients were still alive (Figure 2). In addition to the two in-hospital deaths, six patients (21.4%) died after the hospital discharge. Two (7.1%) deaths were unrelated to pancreas disease: patient 36 died of metachronous lung cancer at day 858 after IAT, and patient 14 died at day 1349 after IAT from a subarachnoid hemorrhage. Two patients (7.1%), who had already liver metastases at the time of pancreas surgery, died\nbecause of disease progression. Patient 4 had a single unresectable liver metastasis from a locally resectable bleeding duodenal adenocarcinoma (pT3pN0pM1, G2): during follow-up, an increase in the size of the metastasis >25% over a 3-month period was detected, together with the appearance of additional liver lesions within 9 months, with the patient dying from liver metastases at day 501 after IAT. Patient 17 (neuroendocrine neoplasm; pT3pN1pM1, G3) had diffuse small liver metastases at the time of surgery, and for this reason IAT was performed in the bone marrow. He died of liver disease progression at day 322 after IAT, without radiologic evidence of tumor localization at the site of islet infusion. Finally, patients 1b and 33, who were disease free after surgery, died due to the relapse of their cancer. Patient 1b (adenocarcinoma of the ampulla of Vater; pT4pN1pM0R0, G3) had peritoneal metastases at day 87\nIAT, islet autotransplantation. 1Including pancreatic fistula, delayed gastric empty, postpancreatectomy hemorrhage, other intra-abdominal complication, and medical complication. 2Potentially serious (Terminology Criteria for Adverse Events score >3).\n1816 American Journal of Transplantation 2016; 16: 1812–1826\nafter IAT and died of malignant bowel obstruction at day 102 after IAT, without evidence of liver metastases. Patient 33 (adenocarcinoma; pT3pN0pM0R1, G2) developed local recurrence at day 362 after IAT with subsequent liver and lung metastases and died at day 933.\nDuring follow-up, 7 (25%) of 28 patients reached insulin independence, 20 (71%) patients had partial graft function, and one (4%) patient had primary graft non function (Figure 3A). Five of 27 patients who gained graft function lost detectable C-peptide overtime (loss at days 30, 255, 731, 1637, and 1890 after IAT), and four of seven subjects who reached insulin independence lost it (days 7, 60, 314, and 338 after IAT) although they maintained partial graft function (Figure 3B). At the last follow-up visit (Figure 4), median fasting C-peptide was 0.65 (0.2–1) ng/mL, insulin requirement was 0.31 (0.12– 0.53) U/kg/day, and HbA1c was 6.7% (6.1–7.5%). At least one episode of severe hypoglycemia occurred during follow-up in three patients after they lost graft function.\nSimultaneous IAT after extended distal pancreatectomy (criterion C) In this group, two (10.5%) of 19 IAT candidates were not transplanted (Figure 1, Table 2): one patient had an islet preparation with an insufficient number of islets (patient 38), and one patient (patient 41) had evidence of intraductal papillary mucinous neoplasm with severe dysplasia on the frozen section of the resected margin. The median number of infused islets was 1036 (594– 1565) IEQ/kg. The median postoperative hospital stay was 9 (7–9.25) days. Nine (53%) of 17 patients had minor postpancreatectomy complications (Table 3), while none had major complication (i.e. grade >2). Complica-\ntions related to IAT occurred in two (11.7%) of 17 patients: a left branch portal vein thrombosis (patient 29), which resolved after anticoagulation therapy, and a liver bleed (patient 50), which resolved without intervention (Table 3). All patients were disease free at their last scheduled follow-up visit (731 109 days; Figure 2). Sixteen (94%) of 17 patients (Figure 3A) gained and maintained insulin independence, while one patient was prescribed small doses of insulin immediately after surgery (median 0.16 U/kg/day, range 0.09–0.63 U/kg/day). Two patients developed modest hyperglycemia at days 60 and 382 and were successfully treated with oral hypoglycemic agents and lifestyle modification, respectively (Figure 3B). At the last follow-up visit, all 17 patients had a stable HbA1c (5.8% [5.3–6.1%]) and showed sustained insulin production (fasting C-peptide: 1.61 ng/mL [1.31–1.87]), with no significant change from presurgical levels (Figure 4). Prevention of severe hypoglycemia occurred in all patients.\nSalvage IAT after relaparotomy (criterion D) In this group, 8 of 21 (38%) IAT candidates were not transplanted (Figure 1, Table 2): islet preparations were considered inadequate due to insufficient number of islet (patients 9 and 57) or bacterial contamination (patients 31, 42, 45, 52, and 62) in seven patients; and one patient (patient 30) developed immediate postpancreatectomy complications contraindicating IAT (massive hemobilia as a consequence of a previous percutaneous biliary drainage for a biliary fistula). The median number of infused islets was 1912 (1191–2476) IEQ/kg. The median postoperative hospital stay was 17 (13.5–24.5) days. According to criterion D, all patients in this group had a grade C postpancreatectomy pancreatic fistula (Table 3), and in nine (69%) patients, complications were life-threatening\nOverall survival (%)\n0 28 17 13 1 18 13 10 2 13 9 10 3 9 7 9 4 6 5 6 5 1 2 3 6 0 1 1\nYears since IAT\nDisease/progression–free survival (%)\nNumber at risk\n100\n80\n60\n40\n20\n0 p=0.064 p=0.19\nP er\nce nt\nag e\n(% )\n7 0 0 0\n0 28 17 13 1 17 13 10 2 12 10 10 3 8 6 8 4 6 5 6 5 1 2 3 6 0 1 1 7 0 0 0\n100\n80\n60\n40\n20\n0\nSimultaneous IAT after total pancreatectomy Simultaneous IAT after extended distal pancreatectomy\nSalvage IAT after relaparotomy\nFigure 2: Follow-up: overall survival and disease/progression-free survival. Probability of overall survival (left) and disease/ progression-free survival (right) after pancreatectomy combined with islet autotransplantation, by eligibility criteria, according to Kaplan–Meier analysis. IAT, islet autotransplantation.\nAmerican Journal of Transplantation 2016; 16: 1812–1826 1817\n(i.e. grade >3): seven patients had septic/hemorrhagic shock, and there were two in-hospital deaths due to fatal bleeding from the gastroduodenal artery (patient 5, day 5 after surgery) and multiorgan failure (patient 34, day 95 after surgery). Complications related to IAT occurred in four (31%) of 13 patients, and in two (15%) of these, they were potentially serious (TCAE score >3; Table 3). Portal vein thrombosis occurred in two patients (patient 1 total and patient 6 left branch; both resolved after anticoagulation therapy with low-molecular-weight heparin). A bleed related to the percutaneous portal vein access procedure occurred in one patient and resolved without intervention. Sepsis (Staphylococcus haemolyticus and Enterococcus faecalis) requiring long-term intravenous antibiotics occurred in one patient (patient 22). On October 1, 2015, the median follow-up was 1825 237 days, and 8 (62%) of 13 patients were still\nalive (Figure 2). In addition to the two in-hospital deaths, three (23%) patients died after the initial hospital discharge. One death (7.7%) was unrelated to pancreas disease: patient 3 died of metachronous colorectal cancer at day 1102 after IAT. Patients 1c and 6 who were disease free after surgery died due to the relapse of their cancer. Patient 1c (ductal adenocarcinoma; pT3pN0pM0R0, G2) developed liver metastasis and died at day 803. Patient 6 (ductal adenocarcinoma; pT3pN0pM0R0, G2) developed local recurrence and lung metastases at day 732 and died at day 1120 without evidence of liver metastasis.\nDuring follow-up, 6 (46%) of 13 patients reached insulin independence; 6 (46%) patients had partial graft function, and one (8%) patient had primary graft nonfunction (Figure 3A). Two of 12 patients who gained graft function did not maintained detectable C-peptide overtime\nA\nSimultaneous IAT after total pancreatectomy\nSimultaneous IAT after extended distal pancreatectomy\nSalvage IAT after relaparotomy\n1818 American Journal of Transplantation 2016; 16: 1812–1826\n(days 168 and 1094 after IAT), and three of six subjects who reached insulin independence lost it (at days 149, 230, and 930 after IAT) although maintaining partial graft\nfunction (Figure 3B). At the last follow-up visit (Figure 4), fasting C-peptide was 0.55 ng/mL (0.3–1.24), insulin requirement was 0.22 U/kg/day (0–0.47), and HbA1c was 6.5% (5.85–8.05%). At least one episode of severe hypoglycemia occurred in two of the three patients after they lost graft function.\nMetabolic follow-up: primary graft function, glycogenic control, and predictor of graft survival and insulin independency after IAT The proportion of patients in each islet function category (insulin independent, partial function, graft loss), regardless of islet yield and eligibility criteria, from 6 months to 3 years after IAT, is shown in Table 4. Because the extent of pancreatectomy is an independent predictor of metabolic outcome (28), we analyzed separately patients treated with partial or total pancreatectomy. Nearly all patients undergoing IAT after partial pancreatectomy achieved insulin independence and maintained it overtime. On the other hand, only 11 (28%) of 39 patients undergoing IAT after total pancreatectomy reached insulin independence; 26 (67%) patients achieved only partial graft function for at least some time, and two (5%) patients had primary nonfunction. Seven of the 37 patients who gained graft function did not maintained detectable C-peptide overtime, and six of 11 subjects lost insulin independence although maintaining partial graft function. In the univariate Cox proportional hazards regression analysis, graft loss was associated with lower number of infused islets (p = 0.017) and a higher volume of infused tissue (p = 0.036) (Figure 5). The multivariate Cox proportional hazard regression model confirmed both variables as independent predictors (islet number: hazard ratio [HR] 0.286 [0.09–0.79], p = 0.018; tissue volume: HR 1.23 [1.003–1.5], p = 0.047). The gain of insulin independence was associated only with the number of infused islets (HR 2.376 [1.27–4.42], p = 0.006).\nValues are percent (n). HbA1c, glycated hemoglobin. 1Percent of patients with mean HbA1c levels over time at <7.0, calculated on patients with at least 90 days of follow-up after hospital discharge.\nAmerican Journal of Transplantation 2016; 16: 1812–1826 1819\nOncology follow-up: recurrence and/or progression of cancer Regardless of the eligibility criteria, 54 of 58 patients who underwent IAT had evidence of pancreatic or periampullary neoplasms at the histological examination of the removed tissue. Twenty-three of 54 patients had neoplasms with no or low malignant potential: all were disease free and alive at their last scheduled follow-up visit (Figure 6A, median follow-up 1460 62 days) with the exception of patients 3 and 36 who died as a result of metachronous unrelated cancer, as reported earlier.\nThirty-one of 54 patients had malignant diseases (Table 5), and 12 received adjuvant chemotherapy and/or radiation therapy after resection. Twenty-two of 31 (71%) were alive and disease free at their last follow-up visit (median follow-up 914 382 days), with the exception of patient 78 who had radiological evidence of lymph nodes and liver metastasis at day 90. Among deceased patients, as reported earlier, three died disease free for causes unrelated to malignant diseases (in-hospital deaths: patients 51 and 53; subarachnoid hemorrhage: patient 14), and two died because of metastatic disease\n1820 American Journal of Transplantation 2016; 16: 1812–1826\nprogression (patients 4 and 17). Relapse was observed only in 5 (12.9%) of 31 patients who were disease free after surgery, and only three of them (patients 33, 1c, and 78) developed ex novo liver metastases (Table 6). We compared overall survival and disease/progressionfree survival of patients with ductal carcinoma treated with IAT to those of patients with ductal carcinoma who had surgery in the same period of time but did not receive IAT (33). Patients undergoing IAT had a better survival than did patients without IAT at a similar stage of disease (i.e. IIA or IIB) (Figure 6B)."
    }, {
      "heading" : "Discussion",
      "text" : "This study documents the feasibility and long-term safety and efficacy of IAT for clinical indications other than chronic pancreatitis, extending our first report on a limited series of cases (28), in terms of both number of patients and duration of follow-up. Our study brings several new insights in the treatment of patients with a severe pancreatic fistula requiring completion pancreatectomy or patients with neoplasms of the pancreatic bodyneck requiring extensive distal pancreatectomy or total pancreatectomy because of an increased anastomotic risk.\nFirst, our data document that a diagnosis of malignant disease in itself is not an exclusion criterion for IAT. About half of our patients had malignant diseases of the pancreas or periampullary region. Until today, few case reports of IAT in patients with malignancy have been published (34–39). In fact, malignancy has been considered an absolute contraindication for IAT because of the perceived risk to disseminate cancer cells through the infusion of islets, which may still contain some exocrine cells even after purification (40). Although we recognize that this is not a randomized trial and there is a potential selection bias, in our cohort of patients the oncologic outcome was even better than that of patients with comparable malignancy who did not received IAT. This was also true when we considered the subgroup of patients with pancreatic ductal cancer (i.e. the condition with the highest potential for dissemination of cancer cells). Although we acknowledge that a randomized clinical trial is needed to confirm this encouraging observation, our present results overcome the legitimate concern expressed by many authors of reinfusing islets isolated from organs with malignancy (40), at least when the negativity of the margins is carefully assessed.\nSecond, our data document that in patients with a nonfibrotic pancreas undergoing pancreaticoduodenectomy,\nAmerican Journal of Transplantation 2016; 16: 1812–1826 1821\nPancreatic ductal adenocarcinoma\nPatient 33 3 0 0 1 2 IIA Yes Local plus liver\nplus lung (362 days)\nYes\n(933 days)\n70 570 (380–759) 1186 (701–1670)\nPatient 1c 3 0 0 0 2 IIA Yes Liver (800 days) Yes\n(803 days)\nPatient 6 3 0 0 0 2 IIA Yes Local plus lung\n(738 days)\nYes (1120)\nPatient 77 3 0 0 0 2 IIA No Disease free\n(148 days)\nNo\nPatient 14 3 0 0 0 3 IIA Yes Disease free\n(1341 days)\nYes (1341)\nPatient 53 3 1 0 0 3 IIB No Disease free\n(68 days)\nYes\n(68 days)\n189 302 (222–381) 553\n(487–618) Patient 44 3 1 0 0 3 IIB No Disease free\n(840 days)\nNo\nPatient 51 3 1 0 1 3 IIB No Disease free\n(3 days)\nYes (3 days)\nPatient 61 3 1 0 0 2 IIB No Disease free\n(398 days)\nNo\nPatient 7 3 1 0 1 3 IIB Yes Disease free\n(1890 days)\nNo\nPatient 15 3 1 0 1 2 IIB Yes Disease free\n(1805 days)\nNo\nAdenocarcinoma of the ampulla of Vater\nPatient 24 2 0 0 0 2 IB N0 Disease free\n(1474 days)\nNo IN IN IN\nPatient 1 2 0 0 0 2 IB No Disease free\n(2365 days)\nNo\nPatient 37 2 0 0 0 1 IB No Disease free\n(839 days)\nNo\nPatient 43 3 0 0 0 3 IIA No Disease free\n(761 days)\nNo IN IN IN\nPatient 12 2 1 0 0 2 IIB Yes Disease free\n(1850 days)\nNo 13 344 (237–450) 564\n(320–807) Carcinoma of the distal bile duct\nPatient 59 3 0 0 0 3 IIA Yes Disease free\n(446 days)\nNo 5 247 (0–626) 722\n(0–1879) Patient 48 3 0 0 0 3 IIA No Disease free\n(724 days)\nNo\nPatient 22 3 0 0 0 1 IIA No Disease free\n(1502 days)\nNo\nPatient 64 2 1 0 0 3 IIB No Disease free\n(362 days)\nNo 4 505 (0–1888) 505\n(0–1888) Patient 67 3 1 0 0 3 IIB Yes Disease free\n(194 days)\nNo\nPatient 11 3 1 0 0 2 IIB Yes Disease free\n(1848 days)\nNo\nAdenocarcinoma of the duodenum\nPatient 1b 4 1 0 0 3 IIIA No Peritoneum\n(87 days)\nYes\n(102 days)\nIN IN IN\nPatient 4 3 0 1 2 2 IV Yes Already liver\nmetastases\nYes\n(501 days)\nIN IN IN\n1822 American Journal of Transplantation 2016; 16: 1812–1826\npreemptive completion pancreatectomy and IAT is a valuable option to limit the risk of anastomosis leakage. Even in expert centers and in the absence of specific individual risks, mortality and morbidity rates after pancreaticoduodenectomy increase significantly in\npatients with a non fibrotic pancreas because of a higher risk of leakage from the pancreatic anastomosis due to the soft and friable parenchyma.\nIn the past, total pancreatectomy was proposed to avoid the risk of pancreaticoenteric leak common in partial pancreatectomy and remove all pancreatic tissue with possible undetectable neoplastic synchronous disease (41, 42). The progressive reduction in the incidence of lifethreatening pancreaticoenteric leaks (43–47) has made total pancreatectomy a less advantageous option, also considering that diabetes requiring insulin inevitably follows total pancreatectomy (48–50). However, recently, several groups have reasserted a role for total pancreatectomy in the treatment of pancreatic diseases (48–51) and, accordingly, our suggestion to associate IAT can further strengthen this strategy. In our cohort, operative mortality and morbidity rates were 7% and 57%, and most of the complications were minor (39.3%). These rates are not higher than expected (51–54) and appear acceptable compared with those achieved in patients considered for a proximal pancreatectomy and carrying significant risk factors (55): mortality up to 33.6%, serious morbidity up to 77.2%, and overall morbidity up to 87.6% (56). Because we documented that the main predictor of metabolic benefit in our patients was the number of transplanted islets, we need now to identify predictors of isolation performance to avoid unproductive and expensive isolations and, more important, total pancreatectomy instead of partial pancreatectomy during elective (nonemergency) pancreatic surgery.\nNeuroendocrine tumor\nPatient 50 3 0 0 0 2 IIA No Disease free\n(734 days)\nNo 5 >1085 >1085\nPatient 40 3 0 0 0 2 IIA No Disease free\n(914 days)\nNo\nPatient 78 3 0 0 0 3 IIA No Lymph nodes plus\nliver (90 days)\nNo\nPatient 54 3 1 0 1 3 IIB No Disease free\n(191 days)\nNo 9 1312 (0–3983) 1312\n(162–2461) Patient 71 3 1 0 0 3 IIB No Disease free\n(119 days)\nNo\nPatient 17 3 1 1 2 3 IV Yes Already liver\nmetastases\nYes\n(322 days)\n4 IN 321\n(0–1796) Duodenal gangliocytic paraganglioma\nPatient 19 2 1 0 0 1 – No Disease free (1649 days)\nNo IN IN IN\nIAT, islet autotransplantation; IN, insufficient number; CT, computed tomography chemotherapy; RT, radiotherapy. 1Data obtained from patients who underwent pancreatoduodenectomy without IAT from November 2008 to April 2013 at San Raffaele Scientific Institute; reported are medians (95% confidence intervals). 2R1 describes positive retroperitoneal margin while the pancreatic stump margins were always negative as for protocol.\nAmerican Journal of Transplantation 2016; 16: 1812–1826 1823\nThird, our data document that completion pancreatectomy for life-threatening pancreaticojejunostomy leakage is a valuable clinical indication for IAT (57). Until now, the fear of spreading an infection and the severity of the concomitant illness limited the use of IAT in these patients. The rate of complications related to IAT in this patient group was not significantly higher than expected (23). Further supporting the safety of the procedure is the mortality rate of 15% recorded in candidates to salvage IAT after relaparotomy, a population with an expected mortality rate of 40% due to the presence of grade C pancreatic fistula (58). Thus, it seems safe to conclude that, if care is taken to correctly wash and prepare the infused islets and to evaluate microbial contamination at the time of infusion, the risks associated to IAT after completion pancreatectomy are not increased compared with those of patients undergoing IAT for other indications.\nThe comparison between the results obtained in our cohort with those reported in patients undergoing pancreatic surgery for chronic pancreatitis is challenging. In fact, patients in our cohort have different baseline demographic characteristics (i.e. much older), have more comorbidities, received purified islets in lower number (the whole pancreas being not available for the digestion due to the presence of pancreatic disease), have different life expectancy due to malignant disease, may be treated with radiotherapy/chemotherapy during the follow-up, etc. The largest series of total pancreatectomy with IAT to date has been reported by Sutherland et al at the University of Minnesota, analyzing 412 patients with chronic pancreatitis (23). When we limit the comparison to the patients in our cohort undergoing total pancreatectomy (n = 41, criteria B and D), as expected, in-hospital deaths were higher (9.7% versus 1.2%) and overall survival lower (1 year: 84% versus 97%; 5 years: 54% versus 90%), while surgical complications requiring reoperation after IAT were similar (13% versus 16%). When compared with the corresponding group in terms of number of transplanted islets (<2500 IEQ/kg), the graft survival at 1 year (81% versus 66%) and 3 years (56% versus 45%) is better in our cohort, although associated with a late lower rate of insulin independence (15% versus 13% at 1 year and 12% versus 0% at 3 years).\nFinally, our data document that extended pancreatectomy plus IAT is a valid alternative in patients with lesions of the body-neck region because it prevents the risk of pancreatic fistula (59) without a relevant increase in the complication rate because of islet infusion. Further, the transplant of autologous islets in this setting was effective in preventing diabetes in almost all patients who would have otherwise been at high risk of developing type 3c diabetes after the extensive pancreas resection (14).\nIn conclusion, we propose extending the clinical indications for IAT on the basis of our experience in patients undergoing pancreatic surgery for both nonmalignant and\nmalignant pancreas diseases, including patients undergoing completion pancreatectomy because of anastomosis leakage after pancreaticoduodenectomy and those with pancreatic anastomosis deemed at high risk of leakage."
    }, {
      "heading" : "Acknowledgments",
      "text" : "This study was supported by the Italian Minister of Health (Ricerca Finalizzata RF-2009-1483387), Ministry of Education, University and Research (PRIN 2008, prot. 2008AFA7LC) and Associazione Italiana per la Ricerca sul Cancro (AIRC, bando 5 x 1,000 N_12182 and Progetto IGN_ 11783). We thank the nursing personnel of the Department of Surgery (San Raffaele Scientific Institute) for their invaluable support caring for the patients in this study."
    }, {
      "heading" : "Disclosure",
      "text" : "The authors of this manuscript have no conflicts of interest to disclose as defined by the American Journal of Transplantation."
    } ],
    "references" : [ {
      "title" : "Use and results of consensus definitions in pancreatic surgery: A systematic review",
      "author" : [ "JC Harnoss", "AB Ulrich", "JM Harnoss", "MK Diener", "MW Buchler", "T. Welsch" ],
      "venue" : "Surgery",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2014
    }, {
      "title" : "Morbidity and mortality of pancreaticoduodenectomy for benign and premalignant pancreatic neoplasms",
      "author" : [ "TE Newhook", "DJ LaPar", "JM Lindberg", "TW Bauer", "RB Adams", "VM. Zaydfudim" ],
      "venue" : "J Gastrointest Surg",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2015
    }, {
      "title" : "Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment",
      "author" : [ "F Paye", "R Micelli Lupinacci", "P Bachellier", "JM Boher", "JR. Delpero" ],
      "venue" : "Br J Surg",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2015
    }, {
      "title" : "Update on the management of pancreatic cancer: Surgery is not enough",
      "author" : [ "D Ansari", "A Gustafsson", "R. Andersson" ],
      "venue" : "World J Gastroenterol",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2015
    }, {
      "title" : "Pancreatic cancer: Advances in treatment",
      "author" : [ "S Mohammed", "G Van Buren Ii", "S. Mohammed" ],
      "venue" : "World J Gastroenterol",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2014
    }, {
      "title" : "Pancreatic cancer: Advances in treatment, results and limitations",
      "author" : [ "Hackert T", "Buchler MW" ],
      "venue" : "Dig Dis",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2013
    }, {
      "title" : "Hospital teaching status and volume related to mortality after pancreatic cancer surgery in a national cohort",
      "author" : [ "M Derogar", "J Blomberg", "O. Sadr-Azodi" ],
      "venue" : "Br J Surg",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2015
    }, {
      "title" : "Improved long-term outcomes after resection of pancreatic adenocarcinoma: A comparison between two time periods",
      "author" : [ "PE Serrano", "SP Cleary", "N Dhani" ],
      "venue" : "Ann Surg Oncol",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2015
    }, {
      "title" : "Improving outcome for patients with pancreatic cancer through centralization",
      "author" : [ "VE Lemmens", "K Bosscha", "G van der Schelling", "S Brenninkmeijer", "JW Coebergh", "IH. de Hingh" ],
      "venue" : "Br J Surg",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2011
    }, {
      "title" : "Improvement of surgical results for pancreatic cancer",
      "author" : [ "W Hartwig", "J Werner", "D Jager", "J Debus", "MW. Buchler" ],
      "venue" : "Lancet Oncol 2013;",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2013
    }, {
      "title" : "Effects of pancreatectomy on nutritional state, pancreatic function and quality of life",
      "author" : [ "JW Park", "JY Jang", "EJ Kim" ],
      "venue" : "Br J Surg",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2013
    }, {
      "title" : "Quality-of-life after total pancreatectomy: Is it really that bad on long-term follow-up",
      "author" : [ "BJ Billings", "JD Christein", "WS Harmsen" ],
      "venue" : "J Gastrointest Surg",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2005
    }, {
      "title" : "Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection",
      "author" : [ "I Epelboym", "M Winner", "J DiNorcia" ],
      "venue" : "J Surg Res",
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2014
    }, {
      "title" : "New-onset diabetes after distal pancreatectomy. A systematic review",
      "author" : [ "De Bruijn KM", "van Eijck CH" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2014
    }, {
      "title" : "How severe is diabetes after total pancreatectomy? A case-matched analysis",
      "author" : [ "KJ Roberts", "G Blanco", "J Webber" ],
      "venue" : "HPB (Oxford)",
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 2014
    }, {
      "title" : "The prevalence and severity of microvascular complications in pancreatic diabetes and IDDM",
      "author" : [ "NS Levitt", "G Adams", "J Salmon" ],
      "venue" : "Diabetes Care",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 1995
    }, {
      "title" : "Angiopathies in pancreatic diabetes resulting from chronic pancreatitis",
      "author" : [ "H Wakasugi", "Y Hara", "M Abe", "Y. Katsuda" ],
      "venue" : "Int J Pancreatol",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 1998
    }, {
      "title" : "Pancreatogenic diabetes: Special considerations for management",
      "author" : [ "Cui Y", "Andersen DK" ],
      "venue" : "Pancreatology",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2011
    }, {
      "title" : "Pancreatogenic diabetes after pancreatic resection",
      "author" : [ "H Maeda", "K. Hanazaki" ],
      "venue" : "Pancreatology",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2011
    }, {
      "title" : "Total pancreatectomy with islet autotransplantation: Summary of an NIDDK workshop",
      "author" : [ "MD Bellin", "A Gelrud", "G Arreaza-Rubin" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2015
    }, {
      "title" : "Systematic review of total pancreatectomy and islet autotransplantation for chronic pancreatitis",
      "author" : [ "K Bramis", "AN Gordon-Weeks", "PJ Friend" ],
      "venue" : "Br J Surg",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2012
    }, {
      "title" : "Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: Indication, surgical techniques, postoperative management, and long-term outcomes",
      "author" : [ "S Chinnakotla", "MD Bellin", "SJ Schwarzenberg" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2014
    }, {
      "title" : "Total pancreatectomy and islet autotransplantation for chronic pancreatitis",
      "author" : [ "DE Sutherland", "DM Radosevich", "MD Bellin" ],
      "venue" : "J Am Coll Surg",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2012
    }, {
      "title" : "Systematic review and meta-analysis: Islet autotransplantation after pancreatectomy for minimizing diabetes",
      "author" : [ "M Dong", "AK Parsaik", "PJ Erwin", "MB Farnell", "MH Murad", "YC. Kudva" ],
      "venue" : "Clin Endocrinol (Oxf)",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2011
    }, {
      "title" : "Islet autotransplantation after extended pancreatectomy for focal benign disease of the pancreas",
      "author" : [ "F Ris", "N Niclauss", "P Morel" ],
      "venue" : "Transplantation",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2011
    }, {
      "title" : "Diabetes-free survival in patients who underwent islet autotransplantation after 50% to 60% distal partial pancreatectomy for benign pancreatic tumors",
      "author" : [ "SM Jin", "SH Oh", "SK Kim" ],
      "venue" : "Transplantation",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2013
    }, {
      "title" : "Autologous islet transplantation in patients requiring pancreatectomy for neoplasm",
      "author" : [ "G Balzano", "L. Piemonti" ],
      "venue" : "Curr Diab Rep 2014;",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2014
    }, {
      "title" : "Extending indications for islet autotransplantation in pancreatic surgery",
      "author" : [ "G Balzano", "P Maffi", "R Nano" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2013
    }, {
      "title" : "25 years of the ricordi automated method for islet isolation",
      "author" : [ "L Piemonti", "A. Pileggi" ],
      "venue" : "Cell R4",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 2013
    }, {
      "title" : "Autologous pancreatic islet transplantation in human bone marrow",
      "author" : [ "P Maffi", "G Balzano", "M Ponzoni" ],
      "venue" : "Diabetes",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2013
    }, {
      "title" : "Comparative evaluation of simple indices of graft function after islet transplantation",
      "author" : [ "A Caumo", "P Maffi", "R Nano" ],
      "venue" : "Transplantation",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2011
    }, {
      "title" : "Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey",
      "author" : [ "D Dindo", "N Demartines", "PA. Clavien" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 2004
    }, {
      "title" : "Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): A prospective observational study in surgical patients",
      "author" : [ "G Balzano", "E Dugnani", "V Pasquale" ],
      "venue" : "Acta Diabetol",
      "citeRegEx" : "33",
      "shortCiteRegEx" : "33",
      "year" : 2014
    }, {
      "title" : "Pancreatic islet autotransplantation with completion pancreatectomy in the management of uncontrolled pancreatic fistula after whipple resection for ampullary adenocarcinoma",
      "author" : [ "F Alsaif", "M Molinari", "A Al-Masloom", "JR Lakey", "T Kin", "AM. Shapiro" ],
      "venue" : "Pancreas",
      "citeRegEx" : "34",
      "shortCiteRegEx" : "34",
      "year" : 2006
    }, {
      "title" : "Total pancreatectomy and islet auto-transplantation as treatment for ampullary adenocarcinoma in the setting of pancreatic ductal disruption secondary to acute necrotizing pancreatitis. A case report",
      "author" : [ "UP yegha", "JA Asghar", "GJ. Beilman" ],
      "venue" : "JOP",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2012
    }, {
      "title" : "Islet autotransplantation combined with total pancreatectomy for treatment of pancreatic adenocarcinoma",
      "author" : [ "X Liu", "S Forster", "U Adam", "W Schmidt", "P Muller", "UT. Hopt" ],
      "venue" : "Transplant Proc",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2001
    }, {
      "title" : "Islet autotransplantation combined with pancreatectomy for treatment of pancreatic adenocarcinoma: A case report",
      "author" : [ "S Forster", "X Liu", "U Adam", "WD Schareck", "UT. Hopt" ],
      "venue" : "Transplant Proc",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2004
    }, {
      "title" : "Autologous islet transplantation after total pancreatectomy for renal cell carcinoma metastases",
      "author" : [ "BL Gala-Lopez", "E Semlacher", "N Manouchehri", "T Kin", "AM. Shapiro" ],
      "venue" : "Am J Transplant",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2013
    }, {
      "title" : "Pancreatic islet autotransplantation after completion pancreatectomy for pancreatic fistula after hemipancreatoduodenectomy for carcinoma",
      "author" : [ "M Kocik", "K Lipar", "F Saudek" ],
      "venue" : "Transplant Proc",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2014
    }, {
      "title" : "Total pancreatectomy with islet autotransplantation in patients with malignancy: Are we there yet",
      "author" : [ "V Dudeja", "GJ Beilman", "SM. Vickers" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 2013
    }, {
      "title" : "Further evaluation of total pancreatectomy",
      "author" : [ "Pliam MB", "ReMine WH" ],
      "venue" : "Arch Surg",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 1975
    }, {
      "title" : "Total pancreatectomy",
      "author" : [ "WH ReMine", "JT Priestley", "ES Judd", "JN. King" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 1970
    }, {
      "title" : "Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: A single-institution experience",
      "author" : [ "CM Schmidt", "O Turrini", "P Parikh" ],
      "venue" : "Arch Surg",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 2010
    }, {
      "title" : "One thousand consecutive pancreaticoduodenectomies",
      "author" : [ "JL Cameron", "TS Riall", "J Coleman", "KA. Belcher" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "44",
      "shortCiteRegEx" : "44",
      "year" : 2006
    }, {
      "title" : "Rates of complications and death after pancreaticoduodenectomy: Risk factors and the impact of hospital",
      "author" : [ "DJ Gouma", "RC van Geenen", "TM van Gulik" ],
      "venue" : "volume. Ann Surg",
      "citeRegEx" : "45",
      "shortCiteRegEx" : "45",
      "year" : 2000
    }, {
      "title" : "Surgical Apgar score predicts perioperative morbidity in patients undergoing pancreaticoduodenectomy at a high-volume center",
      "author" : [ "MM Assifi", "J Lindenmeyer", "BE Leiby" ],
      "venue" : "J Gastrointest Surg",
      "citeRegEx" : "46",
      "shortCiteRegEx" : "46",
      "year" : 2012
    }, {
      "title" : "Perioperative outcomes for open distal pancreatectomy: Current benchmarks for comparison",
      "author" : [ "WH Tseng", "RJ Canter", "RJ. Bold" ],
      "venue" : "J Gastrointest Surg",
      "citeRegEx" : "47",
      "shortCiteRegEx" : "47",
      "year" : 2011
    }, {
      "title" : "Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma",
      "author" : [ "CM Schmidt", "J Glant", "JM Winter" ],
      "venue" : "Surgery",
      "citeRegEx" : "48",
      "shortCiteRegEx" : "48",
      "year" : 2007
    }, {
      "title" : "Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic American Journal of Transplantation",
      "author" : [ "H Nathan", "CL Wolfgang", "BH Edil" ],
      "venue" : "J Surg Oncol",
      "citeRegEx" : "49",
      "shortCiteRegEx" : "49",
      "year" : 2009
    }, {
      "title" : "Is there still a role for total pancreatectomy",
      "author" : [ "MW Muller", "H Friess", "J Kleeff" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "50",
      "shortCiteRegEx" : "50",
      "year" : 2007
    }, {
      "title" : "Total pancreatectomy for pancreatic adenocarcinoma: Evaluation of morbidity and longterm survival",
      "author" : [ "S Reddy", "CL Wolfgang", "JL Cameron" ],
      "venue" : "Ann Surg",
      "citeRegEx" : "51",
      "shortCiteRegEx" : "51",
      "year" : 2009
    }, {
      "title" : "Patient outcomes after total pancreatectomy: A single centre contemporary experience",
      "author" : [ "JA Stauffer", "JH Nguyen", "MG Heckman" ],
      "venue" : "HPB (Oxford)",
      "citeRegEx" : "52",
      "shortCiteRegEx" : "52",
      "year" : 2009
    }, {
      "title" : "Total pancreatectomy for pancreatic cancer: Indications and operative technique",
      "author" : [ "Y Kulu", "BM Schmied", "J Werner", "P Muselli", "MW Buchler", "J. Schmidt" ],
      "venue" : "HPB (Oxford)",
      "citeRegEx" : "53",
      "shortCiteRegEx" : "53",
      "year" : 2009
    }, {
      "title" : "Indications and early outcomes for total pancreatectomy at a high-volume pancreas center",
      "author" : [ "MS Janot", "O Belyaev", "S Kersting" ],
      "venue" : "HPB Surg",
      "citeRegEx" : "54",
      "shortCiteRegEx" : "54",
      "year" : 2010
    }, {
      "title" : "A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy",
      "author" : [ "MP Callery", "WB Pratt", "TS Kent", "EL Chaikof", "Jr. Vollmer CM" ],
      "venue" : "J Am Coll Surg",
      "citeRegEx" : "55",
      "shortCiteRegEx" : "55",
      "year" : 2013
    }, {
      "title" : "Pancreatectomy risk calculator: An ACS-NSQIP resource",
      "author" : [ "P Parikh", "M Shiloach", "ME Cohen" ],
      "venue" : "HPB (Oxford)",
      "citeRegEx" : "56",
      "shortCiteRegEx" : "56",
      "year" : 2010
    }, {
      "title" : "Relaparotomy for a pancreatic fistula after a pancreaticoduodenectomy: A comparison of different surgical strategies",
      "author" : [ "G Balzano", "N Pecorelli", "L Piemonti" ],
      "venue" : "HPB (Oxford)",
      "citeRegEx" : "57",
      "shortCiteRegEx" : "57",
      "year" : 2014
    }, {
      "title" : "Life-threatening postoperative pancreatic fistula (grade C) after pancreaticoduodenectomy: Incidence, prognosis, and risk factors",
      "author" : [ "D Fuks", "G Piessen", "E Huet" ],
      "venue" : "Am J Surg",
      "citeRegEx" : "58",
      "shortCiteRegEx" : "58",
      "year" : 2009
    }, {
      "title" : "Systematic review of central pancreatectomy and meta-analysis of central versus distal pancreatectomy",
      "author" : [ "C Iacono", "G Verlato", "A Ruzzenente" ],
      "venue" : "Br J Surg",
      "citeRegEx" : "59",
      "shortCiteRegEx" : "59",
      "year" : 2013
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Pancreatic surgery is a technically demanding major procedure burdened by a significant rate of complications (1), including death (2,3).",
      "startOffset" : 110,
      "endOffset" : 113
    }, {
      "referenceID" : 1,
      "context" : "Pancreatic surgery is a technically demanding major procedure burdened by a significant rate of complications (1), including death (2,3).",
      "startOffset" : 131,
      "endOffset" : 136
    }, {
      "referenceID" : 2,
      "context" : "Pancreatic surgery is a technically demanding major procedure burdened by a significant rate of complications (1), including death (2,3).",
      "startOffset" : 131,
      "endOffset" : 136
    }, {
      "referenceID" : 9,
      "context" : "As the survival of patients after pancreatic surgery has increased (10), attention has broadened to include patients’ quality of life (11–13).",
      "startOffset" : 67,
      "endOffset" : 71
    }, {
      "referenceID" : 13,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 80,
      "endOffset" : 84
    }, {
      "referenceID" : 14,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 15,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 162,
      "endOffset" : 169
    }, {
      "referenceID" : 16,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 162,
      "endOffset" : 169
    }, {
      "referenceID" : 14,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 258,
      "endOffset" : 268
    }, {
      "referenceID" : 17,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 258,
      "endOffset" : 268
    }, {
      "referenceID" : 18,
      "context" : "Pancreatogenic diabetes mellitus is a common complication of pancreatic surgery (14) and is associated with hypoglycemic episodes (15) and longterm complications (16,17), the latter more likely to occur than in the past because of the longer life expectancy (15,18,19).",
      "startOffset" : 258,
      "endOffset" : 268
    }, {
      "referenceID" : 19,
      "context" : "Islet autotransplantation (IAT) is a valuable option to avoid or minimize postsurgery pancreatogenic diabetes (20).",
      "startOffset" : 110,
      "endOffset" : 114
    }, {
      "referenceID" : 26,
      "context" : "Recently, our group has set forth broader indications for IAT (27,28) and published a small series of patients to explore the possibility of extending IAT to patients with known malignancy having either (i) completion pancreatectomy as treatment for severe pancreatic fistulas, (ii) extensive distal pancreatectomy for neoplasms of the pancreatic neck, or (iii) total pancreatectomy because of preoperative assessment of increased anastomotic risk.",
      "startOffset" : 62,
      "endOffset" : 69
    }, {
      "referenceID" : 27,
      "context" : "Recently, our group has set forth broader indications for IAT (27,28) and published a small series of patients to explore the possibility of extending IAT to patients with known malignancy having either (i) completion pancreatectomy as treatment for severe pancreatic fistulas, (ii) extensive distal pancreatectomy for neoplasms of the pancreatic neck, or (iii) total pancreatectomy because of preoperative assessment of increased anastomotic risk.",
      "startOffset" : 62,
      "endOffset" : 69
    }, {
      "referenceID" : 26,
      "context" : "documented feasibility of “extended” IAT indications for the prevention of postsurgery pancreatogenic diabetes (27,28).",
      "startOffset" : 111,
      "endOffset" : 118
    }, {
      "referenceID" : 27,
      "context" : "documented feasibility of “extended” IAT indications for the prevention of postsurgery pancreatogenic diabetes (27,28).",
      "startOffset" : 111,
      "endOffset" : 118
    }, {
      "referenceID" : 26,
      "context" : "assess eligibility for IAT according to our extended indications (27,28).",
      "startOffset" : 65,
      "endOffset" : 72
    }, {
      "referenceID" : 27,
      "context" : "assess eligibility for IAT according to our extended indications (27,28).",
      "startOffset" : 65,
      "endOffset" : 72
    }, {
      "referenceID" : 26,
      "context" : "Balzano and Piemonti (27) and Table 1].",
      "startOffset" : 21,
      "endOffset" : 25
    }, {
      "referenceID" : 28,
      "context" : "inally described by Ricordi (29), and their number was expressed as islet",
      "startOffset" : 28,
      "endOffset" : 32
    }, {
      "referenceID" : 30,
      "context" : "previously described (31), by the measurement of fasting C-peptide",
      "startOffset" : 21,
      "endOffset" : 25
    }, {
      "referenceID" : 0,
      "context" : "(1) Age >18 years (2) Fasting glycaemia <126 mg/dL without glucose-lowering medications (3) Ability to provide written informed consent (4) Mental stability and ability to comply with study procedures",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 1,
      "context" : "(1) Age >18 years (2) Fasting glycaemia <126 mg/dL without glucose-lowering medications (3) Ability to provide written informed consent (4) Mental stability and ability to comply with study procedures",
      "startOffset" : 18,
      "endOffset" : 21
    }, {
      "referenceID" : 2,
      "context" : "(1) Age >18 years (2) Fasting glycaemia <126 mg/dL without glucose-lowering medications (3) Ability to provide written informed consent (4) Mental stability and ability to comply with study procedures",
      "startOffset" : 88,
      "endOffset" : 91
    }, {
      "referenceID" : 3,
      "context" : "(1) Age >18 years (2) Fasting glycaemia <126 mg/dL without glucose-lowering medications (3) Ability to provide written informed consent (4) Mental stability and ability to comply with study procedures",
      "startOffset" : 136,
      "endOffset" : 139
    }, {
      "referenceID" : 0,
      "context" : "(1) Presence of any multifocal pancreatic neoplasm at preoperative imaging or intraoperative evaluation (2) Diagnosis of intraductal papillary mucinous neoplasm, unless the absence of multifocal lesion is demonstrated by endoscopic ultrasound (3) Involvement of the pathologic pancreatic transsection margin, including any degree of dysplasia or ductal disepithelialization.",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 1,
      "context" : "(1) Presence of any multifocal pancreatic neoplasm at preoperative imaging or intraoperative evaluation (2) Diagnosis of intraductal papillary mucinous neoplasm, unless the absence of multifocal lesion is demonstrated by endoscopic ultrasound (3) Involvement of the pathologic pancreatic transsection margin, including any degree of dysplasia or ductal disepithelialization.",
      "startOffset" : 104,
      "endOffset" : 107
    }, {
      "referenceID" : 2,
      "context" : "(1) Presence of any multifocal pancreatic neoplasm at preoperative imaging or intraoperative evaluation (2) Diagnosis of intraductal papillary mucinous neoplasm, unless the absence of multifocal lesion is demonstrated by endoscopic ultrasound (3) Involvement of the pathologic pancreatic transsection margin, including any degree of dysplasia or ductal disepithelialization.",
      "startOffset" : 243,
      "endOffset" : 246
    }, {
      "referenceID" : 3,
      "context" : "(4) Diagnosis (suspected or ascertained) of multiple endocrine neoplasm (5) Any medical condition that, in the opinion of the investigator, might interfere with the safe completion of IAT",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 4,
      "context" : "(4) Diagnosis (suspected or ascertained) of multiple endocrine neoplasm (5) Any medical condition that, in the opinion of the investigator, might interfere with the safe completion of IAT",
      "startOffset" : 72,
      "endOffset" : 75
    }, {
      "referenceID" : 27,
      "context" : "Percent (n) 100% (28) 100% (17) 100% (13) 100% (58) Postoperative hospital stay (days) 12 (10–15) 9 (7–9.",
      "startOffset" : 17,
      "endOffset" : 21
    }, {
      "referenceID" : 16,
      "context" : "Percent (n) 100% (28) 100% (17) 100% (13) 100% (58) Postoperative hospital stay (days) 12 (10–15) 9 (7–9.",
      "startOffset" : 27,
      "endOffset" : 31
    }, {
      "referenceID" : 12,
      "context" : "Percent (n) 100% (28) 100% (17) 100% (13) 100% (58) Postoperative hospital stay (days) 12 (10–15) 9 (7–9.",
      "startOffset" : 37,
      "endOffset" : 41
    }, {
      "referenceID" : 57,
      "context" : "Percent (n) 100% (28) 100% (17) 100% (13) 100% (58) Postoperative hospital stay (days) 12 (10–15) 9 (7–9.",
      "startOffset" : 47,
      "endOffset" : 51
    }, {
      "referenceID" : 19,
      "context" : "5% (20) Grade 1: any deviation from the normal postoperative course without pharmacologic treatment or surgical, endoscopic, and radiologic interventions 1 3 – 4",
      "startOffset" : 3,
      "endOffset" : 7
    }, {
      "referenceID" : 4,
      "context" : "8% (5) 0% 100% (13) 31% (18) Grade 3: requiring surgical, endoscopic, and radiologic interventions 2 – 4 6",
      "startOffset" : 3,
      "endOffset" : 6
    }, {
      "referenceID" : 12,
      "context" : "8% (5) 0% 100% (13) 31% (18) Grade 3: requiring surgical, endoscopic, and radiologic interventions 2 – 4 6",
      "startOffset" : 15,
      "endOffset" : 19
    }, {
      "referenceID" : 17,
      "context" : "8% (5) 0% 100% (13) 31% (18) Grade 3: requiring surgical, endoscopic, and radiologic interventions 2 – 4 6",
      "startOffset" : 24,
      "endOffset" : 28
    }, {
      "referenceID" : 4,
      "context" : "6% (5) Readmission within 30 days after discharge 21.",
      "startOffset" : 3,
      "endOffset" : 6
    }, {
      "referenceID" : 27,
      "context" : "Because the extent of pancreatectomy is an independent predictor of metabolic outcome (28), we analyzed separately patients treated with partial or total pancreatectomy.",
      "startOffset" : 86,
      "endOffset" : 90
    }, {
      "referenceID" : 18,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 28,
      "endOffset" : 32
    }, {
      "referenceID" : 16,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 38,
      "endOffset" : 42
    }, {
      "referenceID" : 14,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 48,
      "endOffset" : 52
    }, {
      "referenceID" : 10,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 58,
      "endOffset" : 62
    }, {
      "referenceID" : 8,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 68,
      "endOffset" : 71
    }, {
      "referenceID" : 17,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 97,
      "endOffset" : 101
    }, {
      "referenceID" : 15,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 106,
      "endOffset" : 110
    }, {
      "referenceID" : 13,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 115,
      "endOffset" : 119
    }, {
      "referenceID" : 9,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 124,
      "endOffset" : 128
    }, {
      "referenceID" : 7,
      "context" : "Partial pancreatectomy 100% (19) 100% (17) 100% (15) 100% (11) 100% (9) Insulin independence 95% (18) 94% (16) 93% (14) 91% (10) 89% (8) C-peptide <0.",
      "startOffset" : 133,
      "endOffset" : 136
    }, {
      "referenceID" : 38,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 79,
      "endOffset" : 83
    }, {
      "referenceID" : 31,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 89,
      "endOffset" : 93
    }, {
      "referenceID" : 25,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 99,
      "endOffset" : 103
    }, {
      "referenceID" : 21,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 109,
      "endOffset" : 113
    }, {
      "referenceID" : 15,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 119,
      "endOffset" : 123
    }, {
      "referenceID" : 10,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 149,
      "endOffset" : 153
    }, {
      "referenceID" : 18,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 181,
      "endOffset" : 185
    }, {
      "referenceID" : 6,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 190,
      "endOffset" : 193
    }, {
      "referenceID" : 3,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 198,
      "endOffset" : 201
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 205,
      "endOffset" : 208
    }, {
      "referenceID" : 8,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 227,
      "endOffset" : 230
    }, {
      "referenceID" : 20,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 235,
      "endOffset" : 239
    }, {
      "referenceID" : 16,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 244,
      "endOffset" : 248
    }, {
      "referenceID" : 14,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 253,
      "endOffset" : 257
    }, {
      "referenceID" : 8,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 262,
      "endOffset" : 265
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 289,
      "endOffset" : 292
    }, {
      "referenceID" : 3,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 297,
      "endOffset" : 300
    }, {
      "referenceID" : 4,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 305,
      "endOffset" : 308
    }, {
      "referenceID" : 4,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 313,
      "endOffset" : 316
    }, {
      "referenceID" : 6,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 321,
      "endOffset" : 324
    }, {
      "referenceID" : 6,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 349,
      "endOffset" : 352
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 356,
      "endOffset" : 359
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 363,
      "endOffset" : 366
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 370,
      "endOffset" : 373
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 378,
      "endOffset" : 381
    }, {
      "referenceID" : 1,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 414,
      "endOffset" : 417
    }, {
      "referenceID" : 2,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 422,
      "endOffset" : 425
    }, {
      "referenceID" : 2,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 430,
      "endOffset" : 433
    }, {
      "referenceID" : 4,
      "context" : "2 ng/mL 0% 0% 0% 0% 0% % with mean HbA1c < 7% 1 100% Total pancreatectomy 100% (39) 100% (32) 100% (26) 100% (22) 100% (16) Insulin independence 28% (11) Partial graft function 49% (19) 23% (7) 15% (4) 9% (2) 0% Graft loss 23% (9) 65% (21) 66% (17) 68% (15) 56% (9) Primary nonfunction 5% (2) 12% (4) 19% (5) 23% (5) 44% (7) Complete graft loss 18% (7) 6% (2) 8% (2) 9% (2) 13% (2) % with mean HbA1c < 7% 1 65% 6% (2) 12% (3) 14% (3) 31% (5)",
      "startOffset" : 438,
      "endOffset" : 441
    }, {
      "referenceID" : 32,
      "context" : "We compared overall survival and disease/progressionfree survival of patients with ductal carcinoma treated with IAT to those of patients with ductal carcinoma who had surgery in the same period of time but did not receive IAT (33).",
      "startOffset" : 227,
      "endOffset" : 231
    }, {
      "referenceID" : 27,
      "context" : "This study documents the feasibility and long-term safety and efficacy of IAT for clinical indications other than chronic pancreatitis, extending our first report on a limited series of cases (28), in terms of both number of patients and duration of follow-up.",
      "startOffset" : 192,
      "endOffset" : 196
    }, {
      "referenceID" : 39,
      "context" : "In fact, malignancy has been considered an absolute contraindication for IAT because of the perceived risk to disseminate cancer cells through the infusion of islets, which may still contain some exocrine cells even after purification (40).",
      "startOffset" : 235,
      "endOffset" : 239
    }, {
      "referenceID" : 39,
      "context" : "Although we acknowledge that a randomized clinical trial is needed to confirm this encouraging observation, our present results overcome the legitimate concern expressed by many authors of reinfusing islets isolated from organs with malignancy (40), at least when the negativity of the margins is carefully assessed.",
      "startOffset" : 244,
      "endOffset" : 248
    }, {
      "referenceID" : 40,
      "context" : "In the past, total pancreatectomy was proposed to avoid the risk of pancreaticoenteric leak common in partial pancreatectomy and remove all pancreatic tissue with possible undetectable neoplastic synchronous disease (41, 42).",
      "startOffset" : 216,
      "endOffset" : 224
    }, {
      "referenceID" : 41,
      "context" : "In the past, total pancreatectomy was proposed to avoid the risk of pancreaticoenteric leak common in partial pancreatectomy and remove all pancreatic tissue with possible undetectable neoplastic synchronous disease (41, 42).",
      "startOffset" : 216,
      "endOffset" : 224
    }, {
      "referenceID" : 54,
      "context" : "These rates are not higher than expected (51–54) and appear acceptable compared with those achieved in patients considered for a proximal pancreatectomy and carrying significant risk factors (55): mortality up to 33.",
      "startOffset" : 191,
      "endOffset" : 195
    }, {
      "referenceID" : 30,
      "context" : "Percent (n) 100% (31) 100% (23) Median follow-up 914 382 1460 62 Died 29% (9) 8.",
      "startOffset" : 17,
      "endOffset" : 21
    }, {
      "referenceID" : 22,
      "context" : "Percent (n) 100% (31) 100% (23) Median follow-up 914 382 1460 62 Died 29% (9) 8.",
      "startOffset" : 27,
      "endOffset" : 31
    }, {
      "referenceID" : 8,
      "context" : "Percent (n) 100% (31) 100% (23) Median follow-up 914 382 1460 62 Died 29% (9) 8.",
      "startOffset" : 74,
      "endOffset" : 77
    }, {
      "referenceID" : 1,
      "context" : "7% (2) Surgical death 2 – Subarachnoid hemorrhage 1 –",
      "startOffset" : 3,
      "endOffset" : 6
    }, {
      "referenceID" : 21,
      "context" : "Liver (800 days) 1 – Alive 71% (22) 91.",
      "startOffset" : 31,
      "endOffset" : 35
    }, {
      "referenceID" : 0,
      "context" : "2% (1) 0% Lymph nodes plus liver (90 days) 1 –",
      "startOffset" : 3,
      "endOffset" : 6
    }, {
      "referenceID" : 56,
      "context" : "Third, our data document that completion pancreatectomy for life-threatening pancreaticojejunostomy leakage is a valuable clinical indication for IAT (57).",
      "startOffset" : 150,
      "endOffset" : 154
    }, {
      "referenceID" : 22,
      "context" : "The rate of complications related to IAT in this patient group was not significantly higher than expected (23).",
      "startOffset" : 106,
      "endOffset" : 110
    }, {
      "referenceID" : 57,
      "context" : "Further supporting the safety of the procedure is the mortality rate of 15% recorded in candidates to salvage IAT after relaparotomy, a population with an expected mortality rate of 40% due to the presence of grade C pancreatic fistula (58).",
      "startOffset" : 236,
      "endOffset" : 240
    }, {
      "referenceID" : 22,
      "context" : "The largest series of total pancreatectomy with IAT to date has been reported by Sutherland et al at the University of Minnesota, analyzing 412 patients with chronic pancreatitis (23).",
      "startOffset" : 179,
      "endOffset" : 183
    }, {
      "referenceID" : 58,
      "context" : "Finally, our data document that extended pancreatectomy plus IAT is a valid alternative in patients with lesions of the body-neck region because it prevents the risk of pancreatic fistula (59) without a relevant increase in the complication rate because of islet infusion.",
      "startOffset" : 188,
      "endOffset" : 192
    }, {
      "referenceID" : 13,
      "context" : "Further, the transplant of autologous islets in this setting was effective in preventing diabetes in almost all patients who would have otherwise been at high risk of developing type 3c diabetes after the extensive pancreas resection (14).",
      "startOffset" : 234,
      "endOffset" : 238
    } ],
    "year" : 2016,
    "abstractText" : "Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy Pancreatic Surgery Section, Department of General Surgery, IRCCS Istituto Clinico Humanitas, Milano, Italy Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy Units of Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy Clinical Transplant Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy *Corresponding author: Lorenzo Piemonti, piemonti.lorenzo@hsr.it",
    "creator" : "Arbortext Advanced Print Publisher 9.1.531/W Unicode"
  }
}